Hyperhomocysteinemia
Studies in the area of hyperhomocysteinemia reported from K. Ukinc and co-researchers
Published in Pharma Law Weekly, November 24th, 2009
"In this study we aimed to evaluate the effects of MTHFR gene mutation and consequent hyperhomocysteinemia on the development of diabetic microvascular complications in comparison with the other defined risk factors. Diabetic patients without a history of macrovascular complication or overt nephropathy enrolled into the study. The presence of MTHFR 677 C-T point mutation was evaluated by Real-Time PCR...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2009-11-24)
More Articles from Pharma Law Weekly
- AARP Idaho
Idaho's Rising Jobless Rate Fuels State's Growing Health Care Woes - Addiction Medicine
American Lung Association Urges Full Coverage of Clinically Proven Smoking Cessation Treatments - America's Specialty Medicines Companies
Statement of America's Specialty Medicines Companies On House Health Care Bill H.R. 3962 - American Heart Association
Statement by American Heart Association CEO Nancy Brown on Passage of the Affordable Health Care for America Act in the U.S. House of Representatives - American Medical Association
AMA Hails House Passage of Health Reform Bill (H.R. 3962) - American Medical Association
AMA President Kicks Off AMA Meeting Focused on Health Reform - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
